Indivior Pharmaceuticals Inc (INDV)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Indivior Pharmaceuticals Inc

Healthcare (1088)

804-379-1090

10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD

Prossima data di guadagno

Ultimi documenti SEC

INDV's Discussions on Twitter

Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INDV Indivior Pharmaceuticals Inc	34.62	4.46B	1.29B	251.00M	-193.86M	1.9744
TAK Takeda Pharmaceutical Co Adr	18.00	57.90B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.07	43.41B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	36.45	42.89B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	516.77	22.35B	3.17B	1.29B	1.01B	27.09

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-06	Iniziato	H.C. Wainwright	Buy
2025-07-22	Ripresa	Jefferies	Buy
2025-01-28	Iniziato	Rodman & Renshaw	Buy
2024-07-23	Iniziato	Piper Sandler	Overweight
2024-04-03	Iniziato	Craig Hallum	Buy
2023-07-13	Iniziato	Northland Capital	Outperform

Mostra tutto

Indivior Pharmaceuticals Inc Borsa (INDV) Ultime notizie

Indivior Pharmaceuticals Inc Azioni (INDV) Dati Finanziari

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Indivior Pharmaceuticals Inc Borsa (INDV) Ultime notizie

Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance

Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus

Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - Ad-hoc-news.de

Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de

Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace

Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm

Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn

Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView

Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - Sahm

Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView

Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan

Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada

Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis

Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance

Indivior Plc (INDV) News, Articles, Events & Latest Updates - Stocktwits

Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st

Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - uk.finance.yahoo.com

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Exploring a 27% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews

Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV - MarketBeat

Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV - MarketBeat

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha

Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - tradingview.com

Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz

Indivior Pharmaceuticals Inc (INDV) Shares Surge 6.1% -- What GF Score of 75 Tells Investors - GuruFocus

Indivior Pharmaceuticals (INDV) CAO purchases 1,500 common shares - Stock Titan

Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0

Earnings call transcript: Supernus jumps on Indivior merger in Q2 2026 - Investing.com Nigeria

Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com

Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative

Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance

Indivior Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance

Raleigh drug factory part of $2B merger - The Business Journals

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential - DirectorsTalk Interviews

Supernus, Indivior merge to strengthen neuroscience drug portfolio - 1470 & 100.3 WMBD

Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals - stocktitan.net

Supernus and Indivior to merge, forming $2.2B CNS drug company - Dealroom

Supernus Pharmaceuticals (SUPN) outlines investor and employee outreach on Indivior merger of equals - Stock Titan

Indivior Pharmaceuticals, Inc. 2026: Revenue $343M, EPS $0.98— 10-Q Summary - TradingView

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News

Indivior Falls as Investors Reposition Ahead of Second-Quarter Results - Quiver Quantitative

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue - Benzinga

Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook - Yahoo Finance

Supernus Pharmaceuticals (SUPN) details Indivior merger call and planned S-4 proxy filings - Stock Titan

Indivior Pharmaceuticals Inc. R (E7P.MU) Q2 FY2026 & Merger earnings call transcript - Yahoo Finance

CNS-focused Supernus and Indivior agree merger terms - pharmaphorum

Indivior Pharmaceuticals Inc Azioni (INDV) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a INDV